Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Clinical Investigation

• Publication date

  1999-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI4891PMID 9927494PMCID PMC407900
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tyrosine 1101 of Tie2 Is the Major Site of Association of p85 and Is Required for Activation of Phosphatidylinositol 3-Kinase and Akt

  1998cited by this paper
• The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R

  1998cited by this paper
• A novel frizzled gene identified in human esophageal carcinoma mediates APC/beta-catenin signals.

  1998cited by this paper
• Signaling Vascular Morphogenesis and Maintenance

  1997cited by this paper
• Vascular development: cellular and molecular regulation

  1997cited by this paper
• Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

  1997influential reference
• Blood vessel formation: what is its molecular basis?

  1996cited by this paper
• Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.

  1996cited by this paper
• A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype.

  1996cited by this paper
• Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis.

  1996cited by this paper
• Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.

  1996influential reference
• Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis

  1996cited by this paper
• GRB2 and SH-PTP2: potentially important endothelial signaling molecules downstream of the TEK/TIE2 receptor tyrosine kinase.

  1995cited by this paper
• Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

  1995cited by this paper
• The implications of angiogenesis for the biology and therapy of cancer metastasis.

  1994cited by this paper
• Tumors of the Liver

  1994cited by this paper
• Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo.

  1994cited by this paper
• tie2, a putative protein tyrosine kinase from a new class of cell surface receptor.

  1993cited by this paper
• Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.

  1993cited by this paper
• The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors.

  1993cited by this paper
• Primary Liver Cancer in Japan

  1992cited by this paper
• Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment.

  1990cited by this paper
• Hepatology: A Textbook of Liver Disease

  1983cited by this paper

• New insights into biomarkers and risk stratification to predict hepatocellular cancer

  2025cites this paper
• Ang-1 promotes tumorigenesis and mediates the anti-cancer effects of Artesunate on Choroidal melanoma via the regulation of Akt/mTOR signaling pathway.

  2024cites this paper
• Assessment of plasma soluble Tie-2 level to distinguish moyamoya disease from atherosclerotic cerebrovascular disease and predict postoperative neovascularization.

  2023cites this paper
• Clinical Significance of Serum Angiopoietin 2 in Patients with Hepatocellular Carcinoma

  2023cites this paper
• Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development.

  2023cites this paper
• Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma

  2022cites this paper
• The clinical value of angiopoietin‐2 in liver diseases

  2022cites this paper
• Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches

  2021cites this paper
• Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma

  2021cites this paper
• Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma

  2021cites this paper
• In Uveal Melanoma, Angiopoietin-2 but Not Angiopoietin-1 Is Increased in High-Risk Tumors, Providing a Potential Druggable Target

  2021cites this paper
• KYP-2047, an Inhibitor of Prolyl-Oligopeptidase, Reduces GlioBlastoma Proliferation through Angiogenesis and Apoptosis Modulation

  2021cites this paper
• The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma

  2020influential citation
• m in predicting severity of Coronary artery disease

  2020cites this paper
• Expression of Angiopoietins and Angiogenic Signaling Pathway Molecules in Chronic Subdural Hematomas

  2020cites this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin Receptors

  2019cites this paper
• Anti-angiogenic Targets: Angiopoietin and Angiopoietin-Receptors

  2018cites this paper
• Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma

  2018cites this paper
• Hesperidin inhibits angiogenesis, induces apoptosis, and suppresses laryngeal cancer cell metastasis

  2018cites this paper
• Advances in genomic hepatocellular carcinoma research

  2018cites this paper
• Precision medicine based on surgical oncology in the era of genome‐scale analysis and genome editing technology

  2018cites this paper
• Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma

  2017cites this paper
• Autocrine release of angiopoietin-2 mediates cerebrovascular disintegration in Moyamoya disease

  2017cites this paper
• Angiogenesis Dysregulation in Psoriatic Arthritis: Molecular Mechanisms

  2017cites this paper
• Intrahepatic angiopoietin‐2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems

  2017cites this paper
• A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma

  2017cites this paper
• Infectious Angiogenesis—Different Pathways, the Same Goal

  2016cites this paper
• The Evaluation of Angiogenesis Markers in Hepatocellular Carcinoma and Precursor Lesions in Liver Explants From a Single Institution

  2016cites this paper
• Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

  2016cites this paper
• Phase ii trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

  2016cites this paper
• Diagnostic Value of Serum Angiopoietin-2 in Patients with Hepatocellular Carcinoma

  2015cites this paper
• A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2015cites this paper
• Overexpression of angiopoietin‐2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition

  2015cites this paper
• Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study

  2015cites this paper
• Effect of the vascular endothelial growth factor expression level on angiopoietin-2-mediated nasopharyngeal carcinoma growth

  2014cites this paper
• Serum levels of angiopoietin-2, but not angiopoietin-1, are elevated in patients with erythrodermic cutaneous T-cell lymphoma.

  2014cites this paper
• Computational modelling of the angiopoietin and tie interactions

  2014cites this paper
• Cornea Role of Angiopoietin-2 in Corneal Lymphangiogenesis

  2014cites this paper
• Role of angiopoietin-2 in corneal lymphangiogenesis.

  2014cites this paper
• PHIPing out: a genetic basis for tumor ulceration.

  2014cites this paper
• Circulating pro‐ and anti‐angiogenic mediators in patients infected with hepatitis C at different stages of hepatocellular carcinoma

  2014cites this paper
• Angiopoietin 2 as a therapeutic target in hepatocellular carcinoma treatment: current perspectives

  2014cites this paper
• Malformation artério-veineuses cérébrales : d'une amélioration des techniques d'imagerie vers un changement de paradigme des traitements

  2014cites this paper
• Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link

  2013cites this paper
• Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma

  2013cites this paper
• Angiopoietin-2 expression is correlated with angiogenesis and overall survival in oral squamous cell carcinoma

  2013cites this paper
• Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

  2013cites this paper
• Putative effects of potentially anti-angiogenic drugs in rheumatic diseases

  2013cites this paper
• Gene Expression of Growth Factors and Growth Factor Receptors for Potential Targeted Therapy of Canine Hepatocellular Carcinoma

  2013cites this paper
• Angiopoietin2 enhances doxorubin resistance in HepG2 cells by upregulating survivin and Ref-1 via MSK1 activation.

  2013cites this paper
• Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma

  2013cites this paper
• angiogenesis angiopoietin-1 and its potential relationship to myeloma-induced Proangiogenic properties of human myeloma cells: production of

  2013cites this paper
• Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications.

  2012cites this paper
• MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.

  2012cites this paper
• Angiotensin II Induces Angiogenic Factors Production Partly Via AT1/JAK2/STAT3/SOCS3 Signaling Pathway in MHCC97H Cells

  2012cites this paper
• Interação da proteina e2 do vírus da hepatite c com o receptor de ldl e cd81 presentes em células endoteliais e ativação da resposta inflamatória

  2012cites this paper
• Chemotherapy with PLGA microspheres containing docetaxel decreases angiogenesis in human hepatoma xenograft

  2012cites this paper
• Source of angiopoietin-2 in the sera of women during pregnancy.

  2012cites this paper
• Des‐γ‐carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma

  2012cites this paper
• Targeted therapy: its status and promise in selected solid tumors part I: areas of major impact.

  2012cites this paper
• Tie2-Dependent Neovascularization of the Ischemic Hindlimb Is Mediated by Angiopoietin-2

  2012cites this paper
• Molecular targeted therapies in hepatocellular carcinoma.

  2012cites this paper
• Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

  2012cites this paper
• Adenoviral gene therapy in hepatocellular carcinoma: a review

  2012cites this paper
• Angiogenesis and Preeclampsia

  2012cites this paper
• Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies

  2011cites this paper
• Interplay between C-Raf kinase and Rassf1a putative tumour suppressor in liver cancer

  2011cites this paper
• Novel radioimmunotherapy for lymphoma and solid tumours both as a single agent and in combination with the vascular disrupting agents

  2011cites this paper
• AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer

  2011cites this paper
• Comparative Approaches to Characterization of Lymphatic Endothelial Cells as Phenotypically Distinct from Blood Endothelial Cells

  2011cites this paper
• Targeted Therapies for Hepatocellular Carcinoma

  2011cites this paper
• Angiopoietin-2 inhibits the growth of tongue carcinoma without affecting expression of vascular endothelial growth factor.

  2011cites this paper
• The expression of Ang-1, Ang-2 and the Tie-2 receptor in colorectal cancer tissue and its significance

  2011cites this paper
• Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

  2010cites this paper
• Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas.

  2010cites this paper
• HCV-related hepatocellular carcinoma: From chronic inflammation to cancer.

  2010cites this paper
• Placental Vasculature in Health and Disease

  2010cites this paper
• A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

  2010cites this paper
• Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling.

  2010cites this paper
• Reduced plasma levels of Ang-2 and sEng as novel biomarkers in hereditary hemorrhagic telangiectasia (HHT).

  2010cites this paper
• The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma

  2010cites this paper
• Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives

  2010cites this paper
• Hepatitis B virus/hepatitis C virus upregulate angiopoietin‐2 expression through mitogen‐activated protein kinase pathway

  2010cites this paper
• Untersuchung zur transkriptionellen Regulation des Angiopoietin-2 in humanen Endothelzellen

  2010cites this paper
• Angiopoietins.

  2010cites this paper
• Functions Monocytes and Augments Their Inherent Proangiogenic Angiopoietin-2 Regulates Gene Expression in TIE 2-Expressing

  2010cites this paper
• Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions.

  2010cites this paper
• EphA1 receptor silencing by small interfering RNA has antiangiogenic and antitumor efficacy in hepatocellular carcinoma.

  2009cites this paper
• Des-γ-carboxy prothrombinは血管内皮細胞の増殖能と移動能を亢進させる

  2009cites this paper
• The role of the Angiopoietins in vascular morphogenesis

  2009cites this paper
• Mechanisms of Brain Tumor Angiogenesis

  2009cites this paper
• Molecularly targeted therapy for hepatocellular carcinoma

  2009cites this paper
• [Molecularly targeted therapy for hepatocellular carcinoma].

  2009cites this paper
• Serum Levels of Angiopoietin-1, Angiopoietin-2, and Their Receptor Tie-2 in Patients with Nonsmall Cell Lung Cancer During Chemotherapy

  2009cites this paper
• Vasculogenesis and the Origins of Circulation

  2009cites this paper
• The effects of angiopoietin-2 on the growth of tongue carcinoma.

  2009cites this paper
• Molecular Cancer Therapeutics A Human Monoclonal Anti-ANG 2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

  2009cites this paper
• Switching of vascular phenotypes within a murine breast cancer model induced by angiopoietin‐2

  2009cites this paper
• The opening act: vasculogenesis and the origins of circulation.

  2009cites this paper
• Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

  2009cites this paper